Now showing items 1-1 of 1

    • Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. 

      Fuchs, CS; Tabernero, J; Tomášek, J; Chau, I; Melichar, B; Safran, H; Tehfe, MA; Filip, D; Topuzov, E; Schlittler, L; Udrea, AA; Campbell, W; Brincat, S; Emig, M; Melemed, SA; Hozak, RR; Ferry, D; Caldwell, CW; Ajani, JA (2016-10)
      BACKGROUND:Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell ...